Further evidence demonstrates that the antitumor effect of GHRH antagonists is mediated by the suppression of tumor growth through autocrine/paracrine faction rather than regulating the pituitary-GH-hepatic IGF-I axis [21]. Here, IGF1 is linked to neoplasm.